Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic
Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.
Noble Financial Sticks to Their Buy Rating for Tonix Pharma (TNXP)
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Tonix Pharma (TNXP – Research Report), with a price ...
1ARQT, TNXP : Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
On March 24, Tonix Pharmaceuticals Holding announced that the FDA will not require an Advisory Committee meeting for its New ...
Tonix Pharmaceuticals Shares Jump After FDA Guidance for TNX-102
The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...
Tonix says FDA will not require committee meeting for TNX-102 SL NDA
Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration will not require an Advisory Committee meeting to discuss the ...